Harpoon Therapeutics Inc.

20.78+0.2700+1.32%Vol 17.57K1Y Perf 64.04%
Apr 23rd, 2021 10:51 DELAYED
BID20.51 ASK20.82
Open20.50 Previous Close20.51
Pre-Market- After-Market-
 - -%  - -
Target Price
30.17 
Analyst Rating
Strong Buy 1.00
Potential %
44.98 
Finscreener Ranking
★★★+     52.43
Insiders Trans % 3/6/12 mo.
-100/-100/-63 
Value Ranking
     41.06
Insiders Value % 3/6/12 mo.
-100/-100/-77 
Growth Ranking
★★★★     60.00
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-68 
Income Ranking
 —    -
Market Cap673.50M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
69.64 
Earnings Date
5th May 2021

Today's Price Range

20.1621.15

52W Range

10.5525.24

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
2.55%
1 Month
1.84%
3 Months
-5.48%
6 Months
33.70%
1 Year
64.04%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
HARP20.780.27001.32
AAPL133.571.63001.24
GOOG2 293.2825.36001.12
MSFT259.372.20000.86
XOM55.760.49000.89
WFC43.560.86002.01
JNJ165.940.76000.46
FB298.321.80000.61
GE13.550.14001.04
JPM149.682.31001.57
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.58-0.4522.41
Q03 2020-0.55-0.533.64
Q02 2020-0.48-0.51-6.25
Q01 2020-0.38-0.51-34.21
Q04 2019-0.51-0.58-13.73
Q03 2019-0.56-0.65-16.07
Q02 2019-0.65-0.4924.62
Q01 2019-0.41-0.92-124.39
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.4323.21Positive
6/2021 QR-0.4418.52Positive
12/2021 FY-1.8713.02Positive
12/2022 FY-1.8625.60Positive
Next Report Date5th May 2021
Estimated EPS Next Report-0.43
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume17.57K
Shares Outstanding32.41M
Trades Count324
Dollar Volume3.30M
Avg. Volume279.65K
Avg. Weekly Volume142.92K
Avg. Monthly Volume194.40K
Avg. Quarterly Volume248.74K

Harpoon Therapeutics Inc. (NASDAQ: HARP) stock closed at 20.51 per share at the end of the most recent trading day (a 3.85% change compared to the prior day closing price) with a volume of 213.83K shares and market capitalization of 673.50M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 77 people. Harpoon Therapeutics Inc. CEO is Gerald McMahon.

The one-year performance of Harpoon Therapeutics Inc. stock is 64.04%, while year-to-date (YTD) performance is 23.48%. HARP stock has a five-year performance of %. Its 52-week range is between 10.55 and 25.24, which gives HARP stock a 52-week price range ratio of 69.64%

Harpoon Therapeutics Inc. currently has a PE ratio of -10.10, a price-to-book (PB) ratio of 12.04, a price-to-sale (PS) ratio of 43.90, a price to cashflow ratio of 12.20, a PEG ratio of 2.32, a ROA of -27.43%, a ROC of -55.46% and a ROE of -63.81%. The company’s profit margin is -%, its EBITDA margin is -410.00%, and its revenue ttm is $14.15 Million , which makes it $0.44 revenue per share.

Of the last four earnings reports from Harpoon Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.43 for the next earnings report. Harpoon Therapeutics Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Harpoon Therapeutics Inc. is Strong Buy (1), with a target price of $30.17, which is +44.98% compared to the current price. The earnings rating for Harpoon Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Harpoon Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Harpoon Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.31, ATR14 : 1.68, CCI20 : -34.02, Chaikin Money Flow : 0.22, MACD : 0.12, Money Flow Index : 59.14, ROC : -6.13, RSI : 46.26, STOCH (14,3) : 40.48, STOCH RSI : 1.00, UO : 57.64, Williams %R : -59.52), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Harpoon Therapeutics Inc. in the last 12-months were: Georgia L. Erbez (Buy at a value of $101 178), Georgia L. Erbez (Option Excercise at a value of $53 000), Holger Wesche (Option Excercise at a value of $24 000), Holger Wesche (Sold 40 000 shares of value $691 242 ), Natalie Sacks (Option Excercise at a value of $15 578), Natalie Sacks (Sold 7 348 shares of value $92 780 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (100.00 %)
7 (100.00 %)
7 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Harpoon Therapeutics Inc.

Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.

CEO: Gerald McMahon

Telephone: +1 650 443-7400

Address: 131 Oyster Point Blvd, South San Francisco 94080, CA, US

Number of employees: 77

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

62%38%

Bearish Bullish

60%40%

News

Stocktwits